224 related articles for article (PubMed ID: 29678136)
21. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
22. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
[TBL] [Abstract][Full Text] [Related]
23. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
[TBL] [Abstract][Full Text] [Related]
25. Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States.
Hur P; Lomax KG; Ionescu-Ittu R; Manceur AM; Xie J; Cammarota J; Gautam R; Sanghera N; Kim N; Grom AA
Pediatr Rheumatol Online J; 2021 Sep; 19(1):143. PubMed ID: 34521444
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes.
Kullenberg T; Löfqvist M; Leinonen M; Goldbach-Mansky R; Olivecrona H
Rheumatology (Oxford); 2016 Aug; 55(8):1499-506. PubMed ID: 27143789
[TBL] [Abstract][Full Text] [Related]
27. Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades.
Eskola V; Pohjankoski H; Kröger L; Aalto K; Latva K; Korppi M
Acta Paediatr; 2018 Apr; 107(4):577-580. PubMed ID: 29331074
[TBL] [Abstract][Full Text] [Related]
28. Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
Mueller SM; Itin P; Haeusermann P
Dermatology; 2011; 223(2):113-8. PubMed ID: 21967869
[TBL] [Abstract][Full Text] [Related]
29. Cryopyrin-associated periodic syndromes: diagnosis and management.
Miyamae T
Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
[TBL] [Abstract][Full Text] [Related]
30. Longterm followup of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody.
Marsaud C; Marie I; Koné-Paut I
J Rheumatol; 2014 Aug; 41(8):1721-2. PubMed ID: 25086140
[No Abstract] [Full Text] [Related]
31. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
32. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment with anakinra and canakinumab resolves patellar subchondral erosion in neonatal-onset multisystem inflammatory disease.
Leone A; Manna R; Verrecchia E; Cipullo M; Rigante D
Reumatismo; 2019 Apr; 71(1):53-55. PubMed ID: 30932446
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
Yokota S; Imagawa T; Nishikomori R; Takada H; Abrams K; Lheritier K; Heike T; Hara T
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):19-26. PubMed ID: 27974104
[TBL] [Abstract][Full Text] [Related]
35. Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study.
Houx L; Hachulla E; Kone-Paut I; Quartier P; Touitou I; Guennoc X; Grateau G; Hamidou M; Neven B; Berthelot JM; Lequerré T; Pillet P; Lemelle I; Fischbach M; Duquesne A; Le Blay P; Le Jeunne C; Stirnemann J; Bonnet C; Gaillard D; Alix L; Touraine R; Garcier F; Bedane C; Jurquet AL; Duffau P; Smail A; Frances C; Grall-Lerosey M; Cathebras P; Tran TA; Morell-Dubois S; Pagnier A; Richez C; Cuisset L; Devauchelle-Pensec V
Arthritis Rheumatol; 2015 Nov; 67(11):3027-36. PubMed ID: 26245507
[TBL] [Abstract][Full Text] [Related]
36. Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome.
Kilic H; Sahin S; Duman C; Adrovic A; Barut K; Turanli ET; Yildirim SR; Kizilkilic O; Kasapcopur O; Saltik S
Eur J Paediatr Neurol; 2019 May; 23(3):466-472. PubMed ID: 30967326
[TBL] [Abstract][Full Text] [Related]
37. Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics.
Mehr S; Allen R; Boros C; Adib N; Kakakios A; Turner PJ; Rogers M; Zurynski Y; Singh-Grewal D
J Paediatr Child Health; 2016 Sep; 52(9):889-95. PubMed ID: 27650144
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry.
Kuemmerle-Deschner JB; Kallinich T; Henes J; Kortus-Götze B; Oommen PT; Rech J; Krickau T; Weller-Heinemann F; Horneff G; Janda A; Foeldvari I; Schuetz C; Dressler F; Borte M; Hufnagel M; Meier F; Fiene M; Andreica I; Weber-Arden J; Blank N
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38360038
[TBL] [Abstract][Full Text] [Related]
39. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
Feist E; Burmester GR
Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
[TBL] [Abstract][Full Text] [Related]
40. Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan.
Yokota S; Nishikomori R; Takada H; Kikuchi M; Nozawa T; Kanetaka T; Kizawa T; Miyamae T; Mori M; Heike T; Hara T; Imagawa T
Mod Rheumatol; 2013 May; 23(3):425-9. PubMed ID: 23085882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
